Entera Bio Seeks Shareholder Approval for 13.9M Share Plan Increase and Executive Top-up Grants
ENTX has more than doubled off its 52-week low of $0.91.
Summary
Entera Bio's definitive proxy sets a November 24, 2026 vote on a 13.9M share plan increase and executive top-up grants tied to its July $275M private placement.
Key Events · Corporate Governance and Compliance · ENTX
-
13.9M Share Plan Increase
Proposal One seeks approval to increase the 2018 Equity Incentive Plan by 13,937,915 Ordinary Shares, bringing the pool to 10% of outstanding shares minus top-up grants.
-
CEO Top-up Grant
CEO Miranda Toledano would receive 3,351,790 options at $2.96 and 3,351,790 RSUs, restoring her fully diluted ownership to 4.57%.
-
Other Executive Grants
CFO Dana Yaacov-Garbeli (1,595,260 options), COO Hillel Galitzer (1,950,925 options), and R&D Chief Gregory Burshtein (1,540,754 options) each receive one-time grants at $2.96.
-
Special Meeting Date
Shareholders will vote on all eight proposals at a Special Meeting on November 24, 2026, with the record date set for October 1, 2026.
Analysis · ENTX · Life Sciences
The definitive proxy finalizes the equity compensation package tied to the July $275M private placement. Shareholders will vote on November 24, 2026 to approve a 13.9M share increase to the 2018 Equity Incentive Plan and one-time grants to the CEO, CFO, COO, and R&D Chief. The CEO's grant alone includes 3.35M options and 3.35M RSUs, restoring her fully diluted ownership to 4.57%. These grants are designed to retain key executives following the transformative financing, but they also represent significant potential dilution for existing shareholders.
How filings like this one have moved
In the 30 days to Oct 30, 2026, 30.6% of the 1568 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ENTX was trading at $2.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $434.6M. The 52-week trading range was $0.91 to $4.20. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.